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Body weight, waist circumference, blood pressure, and fasting concentrations of plasma glucose, 9 serum free insulin, lipids (HDL and LDL cholesterol and TGs), liver enzymes (AST, ALT and 10 GGT) concentrations were measured as previously described. 9 The MetS was defined and PNPLA3 11 at rs739409 was genotyped as described. 
Statistical analyses 14
Assessment of abundances of TG species. After log2 transformation, the average abundances of TG 15 molecules were compared between the NASH and non-NASH groups by student's t-tests. Multiple 16 comparisons were corrected by using Benjamini-Hochberg's method. 10 
(Supplementary Methods) 17 18
Cluster analysis of lipidomics data. Lipids were grouped by using Bayesian model-based clustering 19 as previously described. Diagnostic model. The biopsy subjects were randomly divided into estimation (n=223) and 22 validation (n=95) groups to build and validate the model, respectively (vide infra). All study 23 subjects (n=318) were used as the second validation group. Shapiro-Wilk's test was used to test the 24 normality of the distribution. The unpaired t-test or Wilcoxon's rank sum test was used to compare 25 the differences between the estimation and validation groups. Normally distributed data are shownM A N U S C R I P T
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as means ± SEM and non-normally distributed data as median followed by the 25 th and 75 th 1 quartiles. Multiple hypotheses testing was performed by using Benjamini-Hochberg's false 2 discovery rate method to calculate q-values. 10 In the data with a large number of variables measured 3 by UPLC, Gibbs sampling algorithm was used for simulation. 12 After sampling for 10000 times, the 4 variables were selected amongst the models based on Bayesian information criterion (BIC). 5
Logistic regression including all the selected variables was used to build the scores. Variables in the 6 scores were finally assessed by backward stepwise regression to identify the optimal NASH score. 7
The area under the ROC-curve (AUROC) was used to describe the diagnostic accuracy of the 8 scores. The optimal cut-off point was calculated using the Youden index. The sensitivity, 9 specificity, positive predictive values (PPV) and negative predictive values (NPV) for relevant cut-10 offs were calculated as described. 6 The AUROCs were compared using the generalized U-11 statistics.
13 One-way analysis of variance was used to compare three groups. Tukey's Honestly 12 Significant Differences test was used for post hoc analyses. A two-sided p-value of less than 0.05 13 was considered as statistically significant. The statistical analyses were performed by using R 14 version 3.0.1 (http://www.r-project.org/). 15 16 17
Results

19
Characteristics of the study groups 20
Comparison of NASH and non-NASH groups (Table 1) 21
Characteristics of the NASH and non-NASH groups are shown in Table 1 . Liver fat content and all 22 liver enzymes were significantly higher in the NASH than the non-NASH group (Table 1) . Features 23 of the MetS (hyperglycemia, hypertriglyceridemia, hypertension and low HDL cholesterol) were 24 significantly more common in the NASH than the non-NASH group. The NASH group had a 25 significantly increased prevalence of the PNPLA I148M variant compared to the non-NASH group Table 1 Tables 2 and 3 ), the NASH group displayed similar 6 abnormalities compared to the non-NASH group as was observed in the entire group (Table 1) . 7 8 Development of a model to predict NASH 9
Comparison of estimation and validation groups (Supplementary
We first developed a model based on clinical parameters and the PNPLA3 genotype alone, then 10 models based on MS-based profiling and finally a model using all data. 11
12
Model based on clinical parameters and I148M variant in PNPLA3 ('NASH Clin Score') 13
To build the 'NASH Clin Score', we used variables differing significantly between NASH and non-14 NASH groups in univariate analysis in the estimation group (Supplementary Table 2 Table 2 . In the NASH as compared to the non-NASH 10 group, significant differences were found in 3 lipid clusters (LC3, LC4, LC6) ( Supplementary Fig.  11 1). We found NASH to be significantly associated with increased concentrations of saturated and 12 monounsaturated TGs (LC4). In contrast, concentrations of sphingomyelins (LC3) and 13 lysophosphatidylcholines (lysoPC) (LC6) were significantly lower in the NASH than the non-14 NASH group ( Supplementary Fig. 1 , Table 2 ). 15
16
Absolute and relative concentrations of TGs 17
Absolute concentrations of circulating TGs between the NASH and non-NASH groups are 18 compared in a heatmap (Fig. 1, panel Table  16 3. 17
18
Metabolomics-based model 19
We also derived a logistic regression model for NASH using the metabolomics data from the 20 estimation cohort. The score based on metabolomics ('NASH Met Score') included 5 selected 21 molecular metabolites, Glu, Ile, Tyr, glycine (Gly) and serine (Ser). The 'NASH Met Score' was as 22 in the validation cohort. In the entire group, the AUROC was 0.866 (95%CI: 0.820, 0.913). The 16 sensitivity was 85.5% and specificity 72.1% (Table 3) . The AUROC of the 'NASH ClinLipMet Score' was significantly higher than that of the 'NASH Lip 10 Score' (p < 0.05), the 'NASH Met Score' (p < 0.001) and the 'NASH Clin Score' (p < 0.01) 11 (p<0.001) (Fig. 3) . Performance of each score is summarized in Table 3 . 12 13
Comparison of NASH to NAFL 14
We also determined whether the MS-based markers in the NASH group were specific to NASH or 15 also observed between NAFL as compared to Non-NAFLD subjects. The clinical characteristics of 16 NASH, NAFL and Non-NAFLD groups are shown in Table 1 . NASH, and NAFL and NAFL and Non-NAFLD. PE40:6 and LysoPC16:0 differed significantly 22 between NASH and NAFL but not between NAFL and controls ( Supplementary Fig. 2) . 23
This is the first study to develop an MS-based model and score for NASH and compare its 2 diagnostic performance to scores based on routinely available data and on PNPLA3 genotype at 3 rs738409. We identified a set of lipids and metabolites that significantly associated with NASH in a 4 liver biopsy cohort of 318 subjects. We performed Gibbs sampling and backward stepwise logistic 5 regression to select variables that fulfilled BIC. A model which included AST, the PNPLA3 6 genotype, fasting insulin, LysoPC(16:0), PE(40:6), Glu, Ile and Gly best predicted NASH (the 7 'NASH ClinLipMet Score'). The AUROC of this score was 0.86, which was significantly higher 8 than that of the 'NASH Lip score', 'NASH Met Score' and the 'NASH Clin Score ', 6 'NASH Liver 9
Fat Score' 6, 9 and the 'NAFLD lipid triplet score'. 14 These data show that MS-based profiling 10 combined with clinical variables may help in the development of non-invasive diagnosis of NASH. 11
12
The NASH as compared to the non-NASH group had an absolute and relative excess of saturated 13 and monounsaturated TGs in their circulating lipidomics profile (Fig. 1 ) TGs containing saturated 14 fatty acids (SFAs) and monounsaturated fatty acid (MUFAs) were previously shown to be 15 overproduced in a study involving 9 subjects by the splanchnic area. 15 De novo lipogenesis 16 produces exclusively SFAs. 16 Stable isotope studies tracing the origin of intrahepatocellular TGs 17 suggest that de novo lipogenesis (DNL) is prominent and perhaps the only abnormal pathway in 18 patients with NAFLD. 17 Hence, circulating TGs containing SFAs and MUFAs might reflect 19 increased DNL. Individual TGs did not, however, remain significant independent predictors of 20
NASH in the final model including both clinical and MS-profiling based parameters (NASH 21
ClinLipMet). This is most likely because of multicolinearity i.e. saturated and monounsaturated TG 22
were were closely correlated with features of IR such as fS-insulin and thus more markers of IR and 23 steatosis than NASH. 24 M A N U S C R I P T Supplementary Fig. 2 ), which were also deficient in NASH, are mostly found in 2 the HDL lipoprotein fraction, which was low in the NASH as compared to other groups. 19 In 14 subjects who underwent a liver biopsy, lysoPC16:0 levels were higher in insulin 6 resistant subjects with a trend toward higher inflammation in their liver. 19 Low lysoPC16:0 7 concentrations were also observed in preadipocyte cultures from 10 metabolically unhealthy as 8 compared to 10 metabolically healthy obese subjects. The metabolite data are consistent with those reported in several small studies. Branch chain amino 11 acids (BCAA) and essential amino acids are increased in obese/insulin-resistant subjects. 21 BCAA 12 also promote IR induced by high fat feeding. Increases in BCAA are accompanied by increases in 13 C3 and C5 acylcarnitines, which are BCAA metabolites in the liver and in skeletal muscle. 22 The 14 increase in the BCAA Ile, and in Glu, which is the first step of BCAA catabolism, could therefore 15 be attributed to the obesity/IR, which is associated with NASH. Increases in Glu have previously 16 been found in studies that included 24 3 and 16 23 patients with NASH. Very recently, a genome-17 scale metabolomics model was constructed to interpret liver transcriptome data in NASH patients. 18
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Altered Glu metabolism was predicted to be the single most abnormal site of metabolism in 19 NASH. 24 The second most common abnormality was predicted to be Ser deficiency, which is 20 known to characterize patients with NASH and insulin resistant as compared to insulin sensitive 21 subjects.
3, 25 Consistently, Ser deficiency also characterized the patients with NASH in the present 22 study. Gly is formed from Ser in a reaction catalyzed by SHMT1, an enzyme leading to Ser 23 formation that was predicted to be down-regulated in NASH. 24 Thus, the observed changes in 24 amino acid concentrations in the NASH as compared to the non-NASH group reflect previouslyM A N U S C R I P T
Use of the predictive equation developed in this study requires set-up of an assay specifically 1 measuring each component. This is feasible given that an increasing number of analytical methods 2 in clinical chemistry laboratories use targeted MS-based methods. 26 Once established and 3 automated, such method requires a minute amount of plasma and is less time-consuming and 4 cumbersome for clinicians than assessment of the different components of especially scores that 5 necessitate inclusion of parameters from physical examination such as waist circumference.
6
Regarding the cost and reproducibility of the "omics" technology, it is important to establish 7 whether screening using the NASH ClinLipMet Score is cost-effective. This can not be performed 8 based on the present study, which is a first step and shows that it is possible to improve the 9 diagnostic accuracy of predictive score for NASH using MS-based analytical platforms in morbidly 10 obese patients with a high prevalence of NASH. 11
12
Limitations of the present study should be considered when interpreting the results. The score was 13 derived from a cohort including a large number of obese patients, which may hamper its application 14 to the general population. Although the histologic criteria for NASH are similar irrespective of 15 obesity, it is important to validate the NASH ClinLipMet Score in a cohort which is not morbidly 16 obese. Treatment with lipid-lowering drugs may influence their plasma lipid levels and play as a 17 potential confounder. However, the performance of the NASH Clin Score', 'NASH Lip Score', 18 'NASH Met Score' and the 'NASH ClinLipMet Score' was not influenced by use of lipid lowering 19 medications, which thus suggest that the scores are robust and that use of lipid lowering 20 medications does not limit usefulness of these scores. The study was cross-sectional and thus the 21 term 'predictor' merely denotes a factor that is associated with risk of NASH. Scores should ideally 22 be validated in a longitudinal study, but such a study is challenging as it is ethically unacceptable to 23 obtain repeated liver biopsies from individuals with no indication for such a procedure. Although
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be missed in 19.4% of those with NASH and 24.7% will be incorrectly diagnosed as having the 1 disease. The score developed in Finnish and Belgian Caucasian subjects may not be valid in other 2 ethnic groups. 3 4
In conclusion, use of MS-based methods helps in improving non-invasive diagnosis of NASH 5 compared to scores relying on routinely available clinical data and PNPLA3 genotype at rs738409. 6
In the present study the findings of increases of the saturated TG 48:0, Glu, Ile, and decreases in 7 The gradient started from 65% A / 35% B, reached 80% B in 2 min, 100% B in 7 min and remained there for 7 min. The flow rate was 0.400 ml/min and the injected amount was 2.0 l (Acquity Sample Organizer, at 10 °C). Reserpine was used as the lock spray reference compound. The lipid profiling was carried out using electrospray ionization mode and the data were collected at a mass range of m/z 300-1200 with a scan duration of 0.2 sec.
The data processing included alignment of peaks, peak integration, normalization and identification.
Lipids were identified using an internal spectral library. The data were normalized using one or Quality control of the method showed that the day-to-day repeatability of control serum samples, and the relative standard deviation for values identified was on average below 25% and 20% for discovery and validation sets, respectively. The internal standards added to all samples in the study had an average relative standard deviation of 25% and 13 % in the discovery and validation sets.
For further identification of unknown lipids, fractions collected from UPLC run were infused to a LTQ-Orbitrap (Thermo Fischer Scientific, San Jose, CA) mass spectrometer by a TriVersa Nanomate (Advion Biosciences, Ithaca, NY) using chip-based nanoelectrospray in positive and negative ionisation mode. Identifications were based on the exact mass and MS n spectra. The instrument was calibrated externally according to the instructions of manufacturer. MS 2 and MS 3 were acquired using either low resolution or high resolution up to target mass resolution R = 60 000 at m/z 400. The normalized collision energies of 30-40% were applied in MS n experiments.
Metabolomic analysis
Polar metabolites are analyzed using using comprehensive two-dimensional gas chromatography combined with time-of-flight mass spectrometry (GC×GC-TOFMS). began at 40 °C with a 2 min hold after which the temperature was programmed to 295 °C at a rate of 7 °C/minute and then held at this temperature for 3 minutes. The second-dimension column temperature was maintained 20 °C higher than the corresponding first-dimension column. The programming rate and hold times were the same for the two columns.
ChromaTOF vendor software (LECO) was used for within-sample data processing, including quantitation of selected target metabolites, and Guineu software was used for alignment, normalization and peak matching across samples. The peaks were first filtered based on number of detected peaks in the total profile of all sample runs. The normalization was performed by M A N U S C R I P T
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correction for internal standards. Other mass spectra from the GC×GC-TOFMS analysis were searched against The Palisade Complete Mass Spectral Library, 600K Edition (Palisade Mass Spectrometry, Ithaca, NY). Data were processed using the Guineu software.
1
After non-targeted profiling of the discovery set, thirteen metabolites were selected for quantitative analysis (amino acids, free fatty acids) which were then quantified in both validation and discovery sets using external calibration curves, after normalization with the labelled group-specific internal standards. Quality control of the method showed that the day-to-day repeatability of control serum samples, and the relative standard deviation (RSD) for values identified was on average below 22%
and 19% for discovery and validation sets, respectively. The internal standards added to all samples in the study had an average RSD of 20% and 18 % in the discovery and validation sets.
Statistical analyses
Assessment of abundances of TG species. Mean and standard errors of abundances of plasma TG molecular species were calculated. After log2 transformation, the average abundances of TG molecules were compared between the NASH and non-NASH groups by student's t-tests. Multiple comparisons were corrected by using Benjamini-Hochberg's method. 10 The comparisons were illustrated by heatmaps, which plot chain lengths of fatty acid against number of double bonds for each TG. R Package, metadar (http://code.google.com/p/metadar) was used for data analysis. Supplementary Tables   Supplementary Table 1 
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